

# ALLIGATOR BIOSCIENCE

## CAPITAL MARKETS DAY

STOCKHOLM ON MAY 29, 2018

## Agenda.

**WELCOME** Charlotte Stjerngren, Moderator

**INTRODUCTION** Per Norlén, CEO

**THE ALLIGATOR STORY** Carl Borrebaeck, Co-founder

**NAVIGATING COMPLEXITY** Peter Ellmark, VP Discovery

**ADC-1013 and ATOR-1015** Charlotte Russell, CMO

*Break 15.30*

**ATOR-1017 and ALG.APV-527** Christina Furebring, SVP Research

**MARKET OVERVIEW** Anu Balandran, VP Business Development

**FINANCE** Per-Olof Schrewelius, CFO

**CONCLUSION** Per Norlén, CEO

**Q&A** Charlotte Stjerngren, Moderator

*Networking 17.00*

### About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit [www.alligatorbioscience.com](http://www.alligatorbioscience.com).